SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update

SCYNEXIS, Inc. (NASDAQ:SCYX) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 678,500 shares, a decrease of 14.7% from the November 30th total of 795,400 shares. Based on an average daily volume of 163,900 shares, the days-to-cover ratio is presently 4.1 days.

Analyst Ratings Changes

Separately, StockNews.com upgraded SCYNEXIS from a “sell” rating to a “hold” rating in a report on Friday, November 8th.

SCYNEXIS Stock Up 1.4 %

Shares of SCYNEXIS stock traded up $0.02 during mid-day trading on Tuesday, hitting $1.09. The stock had a trading volume of 315,934 shares, compared to its average volume of 189,160. The firm has a 50-day moving average of $1.23 and a two-hundred day moving average of $1.56. The firm has a market cap of $41.17 million, a P/E ratio of -1.47 and a beta of 1.50. SCYNEXIS has a 12-month low of $0.90 and a 12-month high of $3.07.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.14. The company had revenue of $0.66 million during the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. Sell-side analysts expect that SCYNEXIS will post -0.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SCYX. XTX Topco Ltd acquired a new position in shares of SCYNEXIS in the 3rd quarter worth approximately $25,000. Geode Capital Management LLC boosted its position in shares of SCYNEXIS by 10.0% during the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock worth $594,000 after buying an additional 36,405 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of SCYNEXIS by 28.4% during the second quarter. Acadian Asset Management LLC now owns 540,683 shares of the company’s stock worth $1,080,000 after buying an additional 119,600 shares during the period. Hedge funds and other institutional investors own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.